Your browser doesn't support javascript.
loading
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
Liu, Hui; Huang, Fen; Zhang, Yu; Wu, Meiqing; Xu, Na; Fan, Zhiping; Sun, Zhiqiang; Li, Xudong; Lin, Dongjun; Xiong, Yiying; Liu, Xiaodan; Lin, Ren; Shi, Pengcheng; Xu, Jun; Wang, Zhixiang; Li, Xiaofang; Sun, Jing; Liu, Qifa; Xuan, Li.
  • Liu H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Huang F; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Zhang Y; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Wu M; Department of Hematology, The First Affiliated Hospital, Guangxi Medical University, Nanning, China.
  • Xu N; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Fan Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Sun Z; Department of Hematology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
  • Li X; Department of Hematology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Lin D; Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
  • Xiong Y; Department of Hematology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
  • Liu X; Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Lin R; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Shi P; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Xu J; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Wang Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Li X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Sun J; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Liu Q; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Xuan L; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Am J Hematol ; 98(3): 408-412, 2023 03.
Article en En | MEDLINE | ID: mdl-36588387
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article